Suppr超能文献

美国当前的州大麻销售限制允许大量用于使用或转移。

Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion.

作者信息

Pacula Rosalie Liccardo, Blanchette Jason G, Lira Marlene C, Smart Rosanna, Naimi Timothy S

机构信息

Department of Health Policy and Management, Price School of Public Policy, University of Southern California, Los Angeles, California; Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California.

Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, Massachusetts.

出版信息

Am J Prev Med. 2021 May;60(5):701-705. doi: 10.1016/j.amepre.2020.11.005. Epub 2021 Feb 12.

Abstract

INTRODUCTION

Legal limits on the amount of cannabis sold per transaction in states with recreational cannabis may promote moderate use and limit diversion. However, state sales limits are heterogeneous and difficult to interpret in terms of tetrahydrocannabinol dose equivalents.

METHODS

This cross-sectional study examined how transaction sales limits on recreational cannabis translate to tetrahydrocannabinol doses among U.S. states allowing commercial cannabis sales as of January 1, 2020. Weight-based quantity limits by cannabis type (flower/bud, concentrates, and edibles) were converted into grams of tetrahydrocannabinol content per transaction using known potency values in 2020.

RESULTS

Weight-based sales limits for flower and concentrate vary considerably across states (range=1.0-2.5 oz for flower and 3.5-15.0 g for concentrate), whereas limits for edible cannabis are heterogeneous. A total of 4 states have independent limits for each product category, and 6 states place limits across all products sold in the transaction. Because no states impose limits on the potency of flower or concentrates, the small differences in the weight-based limits translate into large differences in grams of tetrahydrocannabinol allowed to be sold. Assuming a typical dose of 10 mg of tetrahydrocannabinol, current laws allow for sales of up to 560 (Alaska) to 2,283 (Michigan) doses per transaction on the basis of median product potencies.

CONCLUSIONS

All states allow a large number of tetrahydrocannabinol doses per transaction, larger than what is typically consumed by daily users over a month. States concerned about public health and diversion should consider reducing sales limits and basing them on total tetrahydrocannabinol content across all purchased products.

摘要

引言

在允许休闲大麻使用的州,对每笔交易中出售的大麻数量设置法律限制,可能会促进适度使用并限制大麻转移。然而,各州的销售限制各不相同,且难以用四氢大麻酚剂量当量来解释。

方法

这项横断面研究调查了截至2020年1月1日允许商业大麻销售的美国各州,休闲大麻的交易销售限制如何转化为四氢大麻酚剂量。根据大麻类型(花/芽、浓缩物和 edibles)的基于重量的数量限制,利用2020年已知的效力值,换算为每笔交易中四氢大麻酚含量的克数。

结果

各州花和浓缩物的基于重量的销售限制差异很大(花的范围为1.0 - 2.5盎司,浓缩物为3.5 - 15.0克),而食用大麻的限制则各不相同。共有4个州对每个产品类别有独立的限制,6个州对交易中出售的所有产品设置了限制。由于没有州对花或浓缩物的效力设限,基于重量的限制上的微小差异转化为允许销售的四氢大麻酚克数上的巨大差异。假设典型剂量为10毫克四氢大麻酚,根据产品效力中位数,现行法律允许每笔交易销售多达560剂(阿拉斯加)至2283剂(密歇根)。

结论

所有州每笔交易都允许大量的四氢大麻酚剂量,超过日常使用者一个月通常的消费量。关注公众健康和大麻转移的州应考虑降低销售限制,并以所有购买产品中的总四氢大麻酚含量为依据。

相似文献

1
Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion.
Am J Prev Med. 2021 May;60(5):701-705. doi: 10.1016/j.amepre.2020.11.005. Epub 2021 Feb 12.
2
State Variation in U.S. Medical Cannabis Limits, Restrictions, and Therapeutic Cannabis Dosing.
Cannabis. 2023 Feb 7;6(1):1-8. doi: 10.26828/cannabis/2023.01.001. eCollection 2023.
4
How four U.S. states are regulating recreational marijuana edibles.
Int J Drug Policy. 2017 May;43:83-90. doi: 10.1016/j.drugpo.2017.01.018. Epub 2017 Mar 23.
7
Triangulating web & general population surveys: Do results match legal cannabis market sales?
Int J Drug Policy. 2019 Nov;73:293-300. doi: 10.1016/j.drugpo.2019.06.010. Epub 2019 Jul 2.
8
Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws.
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109159. doi: 10.1016/j.drugalcdep.2021.109159. Epub 2021 Oct 29.
9
Big data on a big new market: Insights from Washington State's legal cannabis market.
Int J Drug Policy. 2018 Jul;57:86-94. doi: 10.1016/j.drugpo.2018.03.031. Epub 2018 Apr 27.
10
A comparative analysis of laws on recreational cannabis edibles between Canada and the United States of America.
Int J Drug Policy. 2021 Aug;94:103191. doi: 10.1016/j.drugpo.2021.103191. Epub 2021 Mar 20.

引用本文的文献

2
Patterns of Cannabis Use among Women With HIV in the United States.
AIDS Behav. 2025 Jun;29(6):2022-2032. doi: 10.1007/s10461-025-04669-z. Epub 2025 Mar 7.
3
Oxidized phospholipid and transcriptomic signatures of THC-related vaping associated lung injury.
Sci Rep. 2024 Dec 30;14(1):31622. doi: 10.1038/s41598-024-79585-8.
4
Cannabis Legalization and Resource Use for Ingestions by Young Children.
Pediatrics. 2024 Jun 1;153(6). doi: 10.1542/peds.2024-065881.
5
Pre-Post Cannabis Legalization for Adult Use: A Trend Study of Two Cohorts of Young Adult Cannabis Users in Los Angeles.
J Psychoactive Drugs. 2025 Jan-Mar;57(1):99-109. doi: 10.1080/02791072.2023.2282515. Epub 2023 Nov 24.
6
Parallel trajectories of vaping and smoking cannabis and their associations with mental and physical well-being among young adults.
Drug Alcohol Depend. 2023 Oct 1;251:110918. doi: 10.1016/j.drugalcdep.2023.110918. Epub 2023 Aug 9.
7
"That's Pot Culture Right There": Purchasing Behaviors of People Who Use Cannabis Without a Medical Cannabis Card.
Cannabis. 2023 Jul 5;6(2):30-46. doi: 10.26828/cannabis/2023/000168. eCollection 2023.
8
Cannabis Retail Market Indicators in Five Legal States in the United States: A Public Health Perspective.
Clin Ther. 2023 Aug;45(8):778-786. doi: 10.1016/j.clinthera.2023.06.015. Epub 2023 Jul 14.
9
State Variation in U.S. Medical Cannabis Limits, Restrictions, and Therapeutic Cannabis Dosing.
Cannabis. 2023 Feb 7;6(1):1-8. doi: 10.26828/cannabis/2023.01.001. eCollection 2023.
10
Cognitive test performance in chronic cannabis flower users, concentrate users, and non-users.
Sci Rep. 2023 May 18;13(1):8068. doi: 10.1038/s41598-023-35217-1.

本文引用的文献

1
Importance of a standard unit dose for cannabis research.
Addiction. 2020 Jul;115(7):1219-1221. doi: 10.1111/add.14984. Epub 2020 Feb 21.
3
Public health implications of legalising the production and sale of cannabis for medicinal and recreational use.
Lancet. 2019 Oct 26;394(10208):1580-1590. doi: 10.1016/S0140-6736(19)31789-1. Epub 2019 Oct 23.
4
'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration.
Addiction. 2020 Jul;115(7):1207-1216. doi: 10.1111/add.14842. Epub 2019 Dec 9.
5
Price and product variation in Washington's recreational cannabis market.
Int J Drug Policy. 2021 May;91:102547. doi: 10.1016/j.drugpo.2019.08.004. Epub 2019 Sep 12.
6
Triangulating web & general population surveys: Do results match legal cannabis market sales?
Int J Drug Policy. 2019 Nov;73:293-300. doi: 10.1016/j.drugpo.2019.06.010. Epub 2019 Jul 2.
9
Adverse health effects of marijuana use.
N Engl J Med. 2014 Jun 5;370(23):2219-27. doi: 10.1056/NEJMra1402309.
10
Adverse health effects of non-medical cannabis use.
Lancet. 2009 Oct 17;374(9698):1383-91. doi: 10.1016/S0140-6736(09)61037-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验